Navigation Links
Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Date:2/20/2008

CJ Acquires Cur Stock for Rights to Spinal Cells in Future

ROCKVILLE, Md., Feb. 20 /PRNewswire-FirstCall/ -- Stem cell company, Neuralstem, Inc. (Amex: CUR), announces that Korean conglomerate, CJ CheilJedang Corporation (KSE: CJ CheilJedang) has purchased an option to negotiate for the exclusive license to Neuralstem's stem cell-products and technology after the company completes a successful human clinical trial. As part of the agreement, CJ has purchased $2.5 million worth of Neuralstem stock at $4.063 per share. The terms of the license will be negotiated after the first successful human trial. CJ exclusive markets will include: Korea, Indonesia, Philippines, Malaysia, Singapore and Vietnam, with a first right of negotiation for China and Japan. Neuralstem is planning to begin human clinical trials this year with its stem cell products.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

"That CJ CheilJedang Corporation, one of Korea's largest conglomerates, with a dominant position in key Asian markets, is acting now to secure future rights to our cells, confirms Neuralstem's leadership position as the stem cell industry matures from research to products in the foreseeable future," said Neuralstem CEO, Richard Garr. "We look forward to benefiting from CJ's superior knowledge of the regulatory pathways in their various markets, which they will share with us as part of this agreement, and to generally expanding the Neuralstem presence overseas through other such agreements."

ABOUT CJ CHEILJEDANG CORPORATION

CJ CheilJedang Corporation is a subsidiary company of CJ Group whose core businesses consists of Food & Food Services, Bio Pharma, Entertainment Media, and Home Shopping & Logistics.

CJ CheilJedang's extensive experience in the pharmaceutical business has positioned it as one of the healthcare leaders in Korea and established a solid foundation to prepare for innovative therapeutics in markets with significant unmet needs. Ongoing investments in the stem cell field represent CJ's commitment to improving the quality of human life. For more information, please visit http://www.CJ.net.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury, and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) in a paper published in the journal TRANSPLANTATION in collaboration with John's Hopkins University researchers and also reversed paralysis in rats with Ischemic Spastic Paraplegia as reported in NEUROSCIENCE on June 29, 2007 in collaboration with researchers at University of California San Diego.

The company has also developed immortalized human neural stem cells for in-vitro use in drug development for the academic and pharmaceutical markets. For further information, please visit http://www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This press release may contain forward-looking information about Neuralstem, Inc., which are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and Neuralstem's future performance, operations and products. This and other "Risk Factors" contained in Neuralstem's public filings with the SEC should be read in connection with this release. For further information on Neuralstem, please review the company's filings with the SEC including periodic reports, including the quarterly report on Form 10- Q for the quarter ended September 30, 2007.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Shares Accepted for Trading on Amex(R)
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... integration, and building management solutions headquartered in Aurora, Ohio, announced the opening of ... Springs, North Carolina, the newly constructed facility is home to 200 employees focused ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... resume cervical and lumbar disc production, company President, Jake Lubinski will be traveling ... implanting the AxioMed disc in Cologne and Karlsruhe to discuss the benefits of ...
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 /PRNewswire/ ... Phase 3 open-label two-year study of rufinamide, which ... the American Epilepsy Society (AES) held from December ... Analysis of final two-year safety, tolerability and cognitive ... with rufinamide experienced similar safety and tolerability profiles, ...
(Date:12/4/2016)... 3, 2016  In five studies being presented today ... Meeting and Exposition in San Diego ... improve the delivery of life-saving treatments to patients with ... designed to carry therapies directly to the sites in ... provide a substantial advantage over traditional, systemic methods. The ...
Breaking Biology Technology:
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
(Date:11/21/2016)... 2016   Neurotechnology , a provider of ... announced that the MegaMatcher On Card fingerprint matching ... the NIST Minutiae Interoperability Exchange (MINEX) III ... steps of the evaluation protocol. ... of fingerprint templates used to establish compliance of ...
Breaking Biology News(10 mins):